Amyotrophic Lateral Sclerosis
-
The Department of Veterans Affairs (VA) is amending its Schedule for Rating Disabilities by revising the disability evaluation criterion provided for amyotrophic lateral sclerosis (ALS) to provide an evaluation of 100 percent for any veteran with service-connected ALS. This change is necessary to adequately compensate veterans who suffer from this progressive, untreatable, and fatal disease. This change is intended to provide a total disability rating for any veteran with service-connected ALS.
-
Although there is no cure for ALS, there are treatment options. However, treatment is designed primarily to manage symptoms. Rilutek is a prescription drug designed to slow the progression of the disease. Some ALS patients also take vitamins and antioxidants to slow the disease progress as well. Counseling can assist with relieving the mental anguish of being diagnosed with a terminal disease; speech therapy can help maintain speech, voice and aid in swallowing; occupational therapy enables the person to function in their environment as independently as possible with the use of adaptive equipment; respiratory therapy provides respiratory care plans essential to supporting a diminishing breathing ability, and the goal of physical therapy is to assist in maintaining joint ROM, muscle s...
-
-
A Pennsylvania jury has awarded $10 million to a man who was misdiagnosed with the fatal disease amyotrophic lateral sclerosis.
Eric Davenport "lived with the belief that he had an incurable, progressive, certainly fatal disease that was going to kill him in very short order," said his attorney, Matthew A. Casey of Ross Feller Casey in Philadelphia, Pa.
-
-
-
ALISO VIEJO, Calif. -- AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced additional data from the subset of patients with amyotrophic latera...
-
To: NATIONAL EDITORS
Contact: Robert Goldstein of ALS TDI, 1+617-441-7295, rgoldstein@als.net, Jim Brown, Vice President - Public Relations of MDA, +1-520-529-5320, jbrown@mdausa.org, Nick Woolf of Oxford BioMedica, +44-1865-783-000, n.woolf@oxfordbiomedica.co.uk
-
Search Over 8,000 People and Over 1,000 Research Organisations
DUBLIN -- Maven Semantic (http://www.mavensemantic.com) announces updates to their Amy...
-
A myotrophic lateral sclerosis (ALS) is a progressive neurological disease that causes severe physical disability and generally leads to death within ...